atural sugar in the management of type-II diabetes mellitus
- Conditions
- Health Condition 1: null- type-II diabetes mellitus
- Registration Number
- CTRI/2011/10/002039
- Lead Sponsor
- Sugen Life Sciences Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 25
Subjects whose fasting blood glucose levels in between 90 mg/dl and 200 mg/dl and normal in blood pressure and other biochemical parameters.
Taking standard medication for the past three months
?Diabetic patients currently under treatment for heart disease, cancer, post-surgical patients, tuberculosis and other chronic diseases.
?Subjects who are smokers, alcoholism, chewing of various tobacco products and usage of drugs
?Subjects who are sedentary/heavy physical activity, under weight and overweight/obesity
?Subjects who are bedridden for chronic diseases for prolonged time and kidney diseases and whose serum creatinine levels are 1.5 mg/dl
?Diabetes patients taking insulin (type-1 diabetes patients)
?Subjects who had cancer, AIDS, HIV, heart failure, major surgery in past 4 years
?Pregnant women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome variables will be NS induced changes in fasting and post-prandial blood glucose levels.Timepoint: Once in a four weeks
- Secondary Outcome Measures
Name Time Method I.Changes in serum concentrations of lipid profile (Total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides and hemoglobin A1c). <br/ ><br>II.Changes in body weight and BMI. <br/ ><br>III.Incidence and severity of adverse events <br/ ><br>Timepoint: Once in a four weeks